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ABSTRACT 
Objective: The main purpose of this work was to prepare tolnaftate (TOL) loaded nanostructured lipid carriers (NLCs), Evaluate its characteristics 
and in vitro release study.  
Methods: Tolnaftate loaded Nanostructured lipid carriers were prepared by the high shear homogenization method using different liquid lipids types 
(DERMAROL DCO® and DERMAROL CCT®) and concentrations, different concentration ratios of tween80® to span20®
Results: The results revealed that NLC dispersions had spherical shapes with an average size between 154.966±1.85 nm and 1078.4±103.02 nm. 
High entrapment efficiency was obtained with negatively charged zeta potential with PDI value ranging from 0.291±0.02 to 0.985±0.02. The release 
profiles of all formulations were characterized by a sustained release behavior over 24 h and the release rates increased as the amount of surfactant 
decreased. The release rate of TOL is expressed following the theoretical model by Higuchi. 
 and different homogenization speeds. 
All the formulated nanoparticles were subjected to particle size (PS), zeta potential (ZP), polydispersity index (PI), drug entrapment efficiency (EE), 
Differential Scanning Calorimetry (DSC), Transmission Electron microscopy (TEM), release kinetics and in vitro release study was determined.  
Conclusion: From this study, It can be concluded that NLCs are a good carrier for tolnaftate delivery 
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INTRODUCTION 
Topical drug conveyance system is a satisfying method for local and 
systemic treatment. The conveyance of medication topically is the 
best treatment for the skin diseases [1]. 
Topical treatment of fungal infections has several advantages such 
as targeting the site of infection, decrease the systemic side effects, 
increase the efficacy of treatment and high patient compliance. 
There are different types of topically effective antifungal drugs used 
in the treatment of dermatological skin infections. The activity of the 
topical antifungal drug depends on the penetration of drugs through 
the target tissue. So, the effective drug concentration levels should 
be achieved in the skin. In the topical administration of antifungals, 
the drug substances should pass through the outermost layer of the 
skin, which called stratum corneum, to reach the lower layers of the 
skin. In this stage, the formulation may play an important role in the 
penetration of drugs into the skin [2]. Several problems may find 
with some topical formulations, e. g. low permeability through the 
stratum corneum so low systemic absorption [3]. Delivery of 
antifungal agent into the skin can be improved with the carriers 
including colloidal systems, vesicular carriers, and nanoparticles [4]. 
Novel drug delivery systems based on lipid nanoparticles can 
increase the permeability of both hydrophilic and lipophilic drugs 
[5]. NLCs made out of a strong lipid network with a sure substance 
of a fluid lipid are another era of lipid nanoparticles. the 
employment of a lipid mix of solid and liquid forms can deform the 
production of a perfect crystal. The particle-matrix contains 
imperfections, providing space to accommodate the drug molecules 
in amorphous clusters [6]. NLCs are viewed as a more advanced era 
of nanoparticles, which have enhanced properties for drug loading, 
adjustment of the delivery profile, and stable medication during 
storage [7-10]. Because of the lipophilic content of the NLCs they are 
considered especially helpful in the administration of lipophilic 
medication. Tolnaftate is a synthetic thiocarbamate with a 
naphthalene, 3-methyl phenyl rings in its structure, and it hinders 
squalene epoxidase [11]. Squalene epoxidase is an essential enzyme 
in the pathway of ergosterol formation (ergosterol is an important 
component of the fungal membrane). The only way for tolnaftate 
activity is to be applied topically; it is inactive when taken orally or 
by other routes [12]. Tolnaftate is found in the market in different 
topical dosage forms with 1% concentration in the form of cream, 
powder, spray and liquid aerosol. But each type has some 
disadvantages. Aerosols cause mild, temporary stinging, while 
creams and gels need longer time for curing and decreases the 
patient compliance because of their poor penetration. The Colloidal 
drug delivery system is used to enhance the permeability of the drug 
without affecting its efficacy [13]. Tolnaftate loaded NLCs provide an 
effective method to increase the release, stability and patient 
compliance of tolnaftate dosage form. The objective of the present 
work was to prepare tolnaftate loaded NLC and evaluate its 
characteristics and in vitro release study.  
MATERIALS AND METHODS 
Materials 
Tolnaftate® (Methyl [3-Methyl Phenyl] Carbamothioic Acid O-2-
Naphthalenyl) was obtained from Sigma Chemical Company, St. 
Louis, USA, Naterol GMS® (Glyceryl stearate) was obtained from 
CISME Italy S. N. C. via Heinrich's commercial agency, Dermarol 
DCO® is an ester of decyl alcohol and oleic acid (Decyl Oleate) was 
obtained from CISME Italy S. N. C. via Heinrich's commercial agency, 
Dermarol CCT® is a mixed tri-ester of glycerin and Caprylic and 
Capric acids (Caprylic/Capric triglyceride) was obtained from CISME 
Italy S. N. C. via Heinrich's commercial agency, Tween 80® 
(Polysorbate80) was obtained from CISME Italy S. N. C. via 
Heinrich's commercial agency, Span 20® (Sorbitan monolaurate) 
was obtained from CISME Italy S. N. C. via Heinrich's commercial 
agency, Lecithin® was obtained from CISME Italy S. N. C. via 
Heinrich's commercial agency, Dialysis tubing cellulose membrane 
(molecular weight cutoff 12,000-14,000 g/mole) was supplied by 
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Sigma-Aldrich (St. Louis, USA), Methanol, Ethanol, and Phosphate 
buffer were of HPLC grade. 
Methods  
Development of calibration curve for tolnaftate 
Tolnaftate was accurately weighed (100 mg) and dissolved in 100 ml of 
media (Ethanol) in 100 ml volumetric flask (concentrated solution). a 
stock solution was prepared by taking 10 ml of a concentrated solution 
in 100 ml of ethanol. Two millimeters of the stock solution were 
withdrawn and diluted up to 10 ml with ethanol in 10 ml volumetric 
flask (standard working solution). The λmax of the drug was determined 
by scanning the dilutions between 200 to 400 nm using a UV-visible 
spectrophotometer (Shimadzu UV spectrophotometer, UV-1601, Japan) 
[11]. From the above standard working solution, 0.5, 1, 1.5, 2 and 2.5 ml 
were withdrawn and diluted up to 10 ml with ethanol in 10 ml 
volumetric flask to get a concentration of 1, 2, 3, 4 and 5 µg respectively. 
The absorbance of each solution was measured by UV-visible 
spectrophotometer (Shimadzu UV spectrophotometer, UV-1601, Japan) 
using ethanol as blank at the previously detected λ max. 
Preparation of tolnaftate loaded NLCs 
Tolnaftate loaded NLCs were prepared by high shear homogenization 
method [14, 15]. Briefly, the lipid phase consisted of Naterol GMS®, as 
solid lipid was melted at 80 °C tolnaftate was dispersed in the melted 
lipid, then mixed with the liquid lipid Dermarol DCO® or Dermarol 
CCT® and added to the Oily surfactants (Span 20® and Lecithin®). An 
aqueous surfactant phase consists of Tween 80® was heated up to the 
same temperature of the molten lipid phase. The hot surfactant solution 
was poured onto the hot lipid phase and homogenization was carried out 
at 12 000 or 18 000 rpm for 4 cycles (2 min with 30 s off) using high 
shear Homogenizer (IKA T25 digital Ultra–Turrax Germany) And leave 
to cool to room temperature. 
Determination of drug entrapment efficiency 
The amount of tolnaftate entrapped within NLC was determined by 
measuring the amount of non-entrapped tolnaftate in supernatant 
recovered after centrifugation [16] using (Hettich centrifuge, Mikro 22 R, 
Germany). The non-entrapped tolnaftate was measured by adding 1 ml 
of tolnaftate loaded NLCs to 9 ml methanol and then this mixture was 
centrifuged for 30 min at-4˚C, then the collected supernatant was filtered 
with (0.2 µm) Millipore membrane filter, diluted with methanol and 
measured spectrometrically at λ =257 nm [17]. 
The following equation was used to calculate the entrapment 
efficiency (E. E %): 
(E ∙ E %) = (W total − W free)/(W total) ×100 
Measurement of particle size and polydispersity index 
Laser diffraction particle size analyzer (Master seizer Hydro MU 
2000S, Malvern MU instruments, United Kingdom) was used to 
measure the Particle size (PS) and polydispersity index (PDI), at 25 
°C for 60 s. The aqueous NLC dispersion was diluted with distilled 
water before analysis. Each sample was measured in triplicate. 
Measurement of zeta potential (ζ) 
The zeta potential (ZP) of NLC dispersions was measured at 25 °C 
using (Malvern Zetasize Nano-ZS90, United Kingdom). Each sample 
was measured in triplicate, the mean value±SD for the three 
replicates was calculated. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (JEOL JEM-2100, Japan) was used 
to examine the morphologies of the NLC. Phosphotungstic acid 2 % 
(W/V) was used to stain one drop of the diluted sample for 30 s and 
placed on copper grids with films for examination. Digital 
Micrograph and Soft Imaging Viewer software were used to perform 
the image capture and analysis, including particle sizing [18]. 
Differential scanning calorimetry (DSC) 
Thermal characteristics of Drug, Lipid, Physical mixture and NLC 
loaded tolnaftate were determined by differential scanning 
calorimetry using (DSC-50 SHIMADZU, Japan). Samples containing 3 
mg were weighed accurately into standard aluminum pans using an 
empty pan as a reference. DSC scans were recorded at a heating and 
cooling rate of 10 °C/min. The samples were heated from 30-150 °C 
and cooled from 150-30 °C. In vitro antifungal activity of Tolnaftate 
nanostructured lipid carrier compared to the generic Tolnaftate 
against Candida albicans. 
Candida albicans isolates 
Ten C. albicans isolates were provided from the department of 
Microbiology and Immunology, College of Pharmacy-Suez Canal 
University. The isolates were saved on Sabouraud Dextrose Agar 
media.  
Fungal suspensions preparation 
Sabouraud Dextrose Agar (SDA) plates were prepared and sterilized 
by autoclaving at 121 °C for 15 min. Fungal suspensions were 
prepared from fresh 24 h cultures. Five isolated colonies were 
suspended in sterile saline. After thorough mixing with a Vortex 
mixer, the turbidity of the suspension was adjusted to match that of 
a McFarland 0.5 turbidity standard at 530 nm [19, 20].  
Preparation of working solution of tolnaftate nanostructured 
lipid carriers and tolnaftate solution 
The prepared formula was poorly water soluble and was dissolved 
in Dimethyl Sulfoxide (DMSO), the final DMSO concentration used 
was shown not to influence fungal growth. One milliliter of 1% (250 
mg/25 ml) nanoparticle formula was added to 5.25 ml of solvent 
(DMSO) so the concentration becomes 1600 ug/ml. Two-fold serial 
dilution with DMSO diluent was performed from the first tube so the 
concentrations in the following nine tubes became (800, 400, 200, 
100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, and 0.39) ug/ml. From the 
0.5% (250 mg/50 ml) tolnaftate solution, 2 ml were taken and were 
added to 4.25 ml of solvent (96% ethanol) so the conc. becomes 
1600 ug/ml. Two-fold serial dilutions were performed with sterile 
water as previously explained.  
Agar cup-plate method 
One hundred microliters of McFarland 0.5 turbidity standardized 
fungal suspension was placed in a sterile plastic petri dish. Ten 
milliliters of sterile SDA were poured and mixed well with the fungal 
suspension, let harden. Each plate was divided into four equal 
portions along the diameter; four wells of 5 mm diameters were 
prepared via sterile borer in each petri-plate [20]. For each Candida 
albicans isolate, three SDA plate was used for each formula as follow: 
One hundred microliters from each concentration (starting from 
conc. 100 ug/ml) were placed in each well (four concentrations in 
each plates) in addition to two negative control wells (inoculated 
with sterile water and DMSO) and positive control plate which was 
seeded with the test organism. The prepared plates were maintained 
at room temperature for 2 h to allow the diffusion of the solutions in 
to the medium and then incubated at 28 °C for 48 h. The diameter of 
zones of inhibition surrounding each of the well was recorded using 
standard ruler. The experiment was repeated twice for each isolate.  
Broth microdilution method  
Sabouraud Dextrose Broth (SDB) tubes were prepared and sterilized 
by autoclaving at 121 °C for 15 min. In a 96-well microtiter plate, 
100 ul of the prepared formula Nano formula or tolnaftate solution 
(as previously diluted) were taken and placed in the 1st well of 
microtitre plate. 50 ul of sterile saline were added in each of the 
remaining wells, 50 ul from the first well were taken to be serially 
diluted by placing them in the second well and continued serial 
dilution to the last well of the raw, the excess 50 ul from the 10th
One ml of inoculum standardized with 0.5 McFarland was diluted 
with SDB (1:100) to obtain 1-2X10
 well 
were discarded [20].  
6CFU/ml. (Therefore, 0.02 ml of 
inoculum after comparing with 0.5Mcfarland is diluted with 1.98 ml 
of SDB. 50ul of inoculum were then added into each of the prepared 
wells (each well containing 5X104 CFU/ml in 100 ul vol.). In addition 
to positive control well with inoculum without antifungal agent and 
negative control well with diluted antifungal drug formula without 
Gardouh et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 7, 109-115 
 
111 
inoculum. The microtiter plates were then incubated at 28 °C for 
(24–48) h. The experiment was repeated twice for each isolate. The 
minimum inhibitory concentration will be calculated by the sum of 
the concentrations of the last well show no growth and the first well 
show turbidity. 
In vitro release studies 
The in vitro release studies were performed by using a dialysis bag 
diffusion technique [21]. Before using the dialysis bag (molecular 
weight cut off 12000–14000) it was soaked in deionized water for 
12 h [22]. The cellulose bag was filled with the NLC dispersions 
equivalent to 2.5 mg of drug and tied at both ends and placed in a 
beaker containing 50 ml of phosphate buffer (pH 5.5), temperature 
and speed were maintained at 32 °C and 100 rpm, respectively[23]. 
Samples were withdrawn at predetermined time intervals, and the 
same volume was replaced with the fresh buffer to maintain the sink 
condition. Samples were analyzed at 257 nm using UV 
spectrophotometer (Shimadzu UV-1601, Japan). The cumulative 
percent of drug released was plotted against time. The order of the 
drug released from the different formulations was determined 
through analysis of the data using linear regression equations (zero 
order, first order or Higuchi diffusion model). 
Release Kinetics 
In vitro release data were analyzed according to zero-order [24] 
(cumulative % release vs. time), first order [25] (log % drug 
remaining vs. time), and Higuchi’s model [26] (cumulative % drug 
release vs. square root of time). The goodness of fit was evaluated 
using the determination coefficient (R2
RESULTS AND DISCUSSION 
). Korsmeyer–Peppas kinetic 
model was also used to describe the release mechanism applying the 
equation mt/m∞= ktn where mt/m∞ is the fraction of drug 
released, k is the kinetic constant, t is the release time, and n is the 
diffusional exponent for drug release and it equals the slope of log 
mt/m∞ vs. log time curve [27]. The model with the highest 
correlation coefficient (r2) was considered to describe LE release 
from the prepared formulations. 
Standard curve for tolnaftate 
The UV absorbance of tolnaftate standard solutions was in the range 
of 10-50µg/ml of drug in ethanol showed linearity at 257 nm. The 
linearity was plotted for absorbance (Abs) against concentration 
(µg/ml) with R2
 
 value of 0.9947 and with the slope equation y 
=0.0116x+0.0034 as shown in fig. 1. 
 
Fig. 1: Standard calibration curve of tolnaftate in UV spectrophotometer 
 
Preparation of tolnaftate loaded NLCs 
Nine different tolnaftate loaded NLCs formulations produced by 
high shear homogenization method [28] are presented in tables 1 
and 2. We used Naterol GMS® as solid lipid in a concentration of 
10% (w/w), Dermarol DCO® or Dermarol CCT® as liquid lipids in a 
concentration of 90% (w/w) with 1% tolnaftate and stabilized by 
1% (w/w) lecithin® as co-surfactant and different ratios of 
surfactant concentrations Tween80® and Span20®
 
 (2.5/1, 5/1, 
10/1, 15/1) w/w%. The formulation (NLC 45R) showing low 
particle size and high drug release were chosen for DSC and 
microbiological assay. 
Table 1: Structure of tolnaftate loaded NLC formulae prepared at 18,000 Rpm using liquid lipid dermarol CCT® or dermarol DCO®
Formulae code 
 and 
different surfactant ratio 
Naterol GMS (w/w%) Liquid lipid (w/w%) Type of liquid lipid Tween/Span 
NLC9R 10% 90% DCO 2.5/1 
NLC45R 10% 90% CCT 2.5/1 
NLC54R 10% 90% CCT 5/1 
NLC72R 10% 90% CCT 15/1 
 
Table 2: Structure of tolnaftate loaded NLC formulae prepared at 12,000 Rpm using liquid lipid dermarol CCTP®P or dermarol DCOP®P and 
different surfactant ratio 
Formulae code Naterol GMS (w/w%) Liquid lipid (w/w%) Type of liquid lipid Tween/Span 
NLC36 10% 90% DCO 15/1 
NLC45 10% 90% CCT 2.5/1 
NLC54 10% 90% CCT 5/1 
NLC63 10% 90% CCT 10/1 
NLC72 10% 90% CCT 15/1 
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Measurement of polydispersity index zetasize and zeta 
potential of loaded NLCs 
The mean particle size, polydispersity index and zeta potential of TOL 
loaded NLCs are presented in table 3. The sizes of all NLCs formulae 
are ranging from 154.966±1.85 nm to 1060.1±86.08 nm. The results 
reveal that the particle size increase with increasing the surfactant 
concentration ratio, at a high surfactant concentration some surfactant 
molecules may increase the local osmotic pressure, which causes 
moving of continuous phase between some droplets to them, and this 
cause depletion of the continuous phase between the drops and the 
aggregation happened and so the particle size increase [29]. The 
polydispersity index is a ratio that indicates the homogeneity of the 
distribution of the particle size in the system. A homogeneous and 
monodisperse population resulted when the PDI value lower than 0.3 
[30]. For TOL loaded NLCs, PDI values ranged from 0.291±0.02 nm to 
0.985±0.02 nm indicating wide particle size distribution only NLCs 
45R with surfactant ratio 2.5/1 w/w % formula indicating 
homogenous population as presented in table III. The uniformity of the 
vesicle size in the formulation decrease as the polydispersity index 
increase [31]. The zeta potential value affects the stability of colloidal 
dispersion [22]. For stable nanoparticles system the zeta potential 
value should be above+30 mv or below-30 mv [32]. The results of TOL 
loaded NLCs showed relatively good stability and dispersion quality. 
  
Table 3: Particle size, zeta potential, PDI and EE (%) of TOL loaded NLC 
Formula E. E. (%) PS (nm) ZP (mv) PDI 
NLC9R 76.05±0.18 166.16±5.32 -27.96±1.72 0.451±0.03 
NLC45R 78.85±0.69 154.966±1.85 -29.6±0.2 0.291±0.02 
NLC54R 80.70±1.03 270.33±16.31 -23.46±1.94 0.754±0.11 
NLC72R 86.0±0.65 1060.1±86.08 -15.53±0.37 0.985±0.02 
NLC36 83.89±0.72 198.233±11.73 -20.7±1.22 0.455±0.06 
NLC45 69.02±0.36 195.56±7.17 -29.33±0.49 0.482±0.03 
NLC54 81.09±0.71 225.73±7 -27.33±2.15 0.505±0.09 
NLC63 82.30±0.71 422.88±57.92 -19.2±1.1 0.702±0.09 
NLC72 86.61±1.19 687.96±63.76 -16.8±0.75 0.965±0.04 
NLC nanostructured lipid carrier E. E entrapment efficiency, PS particle size ZP zeta potential, PDI polydispersity index, (mean±SD, N=3) 
 
 
Fig. 2: In vitro release profile of tolnaftate and effect of (A) Surfactant ratio on release of tolnaftate loaded NLC prepared at 
homogenization speed 18,000 rpm, (B) surfactant ratio on release of tolnaftate loaded NLC prepared at homogenization speed 12,000 
rpm, (C) lipid type on release of tolnaftate loaded NLC prepared at homogenization speed 18,000 rpm, (D) lipid type on release of 
tolnaftate loaded NLC prepared at homogenization speed 12,000 rpm, (E) homogenization speed on release of tolnaftate loaded NLC 
prepared at surfactant ratio 2.5/1, (F) homogenization speed on release of Tolnaftate loaded NLC prepared at surfactant ratio 5/1 and (G) 
homogenization speed on release of tolnaftate loaded NLC prepared at surfactant ratio 15/1 
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In vitro release study  
The in vitro drug release profiles of TOL loaded NLCs are shown in 
fig. [2]. The release of TOL from the NLC particles was investigated 
for 24 hr. The maximum amount of TOL released was found in the 
formulation (NLC 45R) as shown in fig. 2. The high liquid lipid conc. 
resulted in high drug release, which can be explained by the 
adherence of liquid lipid to the lipid matrix and a subsequent 
reduction in the diffusion path length of the lipid matrix [22]. 
Increasing the surfactant ratio cause particle aggregation and 
increased particle size, so a decrease in surface area and drug 
release was found [29]. The release profile increased by using 
Dermarol CCT® Release Kinetics  as liquid lipid due to its effect on decreasing the 
particle size and the following increase in drug solubilization and 
release potential [33]. As shown in fig. [2] increasing the 
homogenization speed led to an increase in drug release. during 
particle production by the hot homogenization technique, drug 
partitions from the liquid oil phase to the aqueous water phase, so 
the solubility of the drug increase in water and the amount of drug 
partitioning to the water phase will increase. The higher the 
temperature, the greater is the solubility of the drug in the water 
phase, so the amount of drug in the outer shell increased and 
released in a relatively rapid way [34]. The release data are analyzed 
according to zero, first order and Higuchi equations which are 
widely used in determining the release kinetics of lipid 
nanoparticles. The release rate of TOL is expressed following the 
theoretical model by Higuchi as the amount of TOL released from the 
NLC formulations studied showed a linear relationship with the 
square root of time [35]. 
In vitro release data were best explained by the Higuchi model for all 
formulations suggesting diffusion-controlled release table 4. 
Accordingly, the exponent (n) values, particularly for gels and drops, 
were 0.5˂ n ˂ 1, indicating non-Fickian diffusion mechanism [27]. 
 
Table 4: Kinetic modeling of drug release data in NLCs formula 
Formula code Correlation coefficient (r) Release Kinetics Korsmeyer peppers 
Zero First Higuchi r P2 N Mechanism 
NLC9R 0.8177 0.8954 0.9516 Higuchi 0.9642 0.5726 Non-Fickian 
NLC45R 0.8698 0.9589 0.9748 Higuchi 0.9807 0.5673 Non-Fickian 
NLC54R 0.8305 0.8711 0.9461 Higuchi 0.9753 0.6288 Non-Fickian 
NLC72R 0.8822 0.9083 0.9589 Higuchi 0.9797 0.7977 Non-Fickian 
NLC36 0.8209 0.8609 0.941 Higuchi 0.9714 0.6779 Non-Fickian 
NLC45 0.8191 0.8494 0.9297 Higuchi 0.9656 0.7238 Non-Fickian 
NLC54 0.8514 0.8885 0.9514 Higuchi 0.9548 0.7284 Non-Fickian 
NLC63 0.8958 0.9239 0.9655 Higuchi 0.9685 0.7603 Non-Fickian 
NLC72 0.8937 0.9201 0.9618 Higuchi 0.9717 0.8076 Non-Fickian 
Drug 0.7386 0.7452 0.8955 Higuchi 0.6886 0.9164 Non-Fickian 
 
 
Fig. 3: Transmission electron micrographs of (A) NLC 9R, (B) NLC 45R, (C) NLC 54R, (D) NLC 72R, (E) NLC 36, (F) NLC 45, (G) NLC 54, (H) 
NLC 63 and (I) NLC 72, displaced for better visualization 
 
Transmission electron microscopy (TEM) 
The results of TEM imaging of TOL loaded NLC, which are shown in 
fig. [3] indicate that the particles had nanometer-size spherical 
shapes, and no drug crystal was noticed [36]. 
Differential scanning calorimetry (DSC) 
DSC is used to determine the melting and recrystallization 
performance of crystalline material like NLCs [37]. DSC studies were 
carried out to confirm compatibility. The physical state of the NLC lipid 
matrix should be in the form of solid. DSC studies showed that all 
formulations having a melting point over 40 °C which represents the 
solid state at room temperature [38]. The thermal behavior of drug, 
Dermarol CCT, physical mixture compared with the thermal behavior 
of TOL loaded NLC formulae in the range of 20-200 °C are shown in fig. 
[4]. The DSC heating curves were recorded as a plot of enthalpy (m/w) 
vs. temperature ( °C) [39]. TOL thermogram demonstrates a sharp 
endothermic peak at 111.97 °C. A sharp endothermic peak at 61.89 °C 
was observed for Dermarol CCT. Two sharp endothermic peaks at 
60.02 °C and 105.58 °C were shown for the physical mixture 
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thermogram. The endotherm of the drug was absent in the 
thermograms of TOL loaded NLC. This absence indicates that the drug 
was completely solubilized inside the lipid matrix of the NLC or an 
amorphous dispersion of TOL in the lipid matrix is formed. For the less 
ordered crystal, the melting of the substance requires less energy than 
the perfect crystalline substance. Some studies show that if the 
substance has a high melting point value, this would suggest highly 
ordered lattice arrangement [40]. It is thought that increase the 
surface area of the amorphous form lead to increase its energy which 
lead to increase the solubility, dissolution rates and bioavailability of 
the incorporated drug [41]. In the final NLC formulation, a decrease in 
the melting point of the lipid, from 60.02 °C to 57.26 °C due to the 
incorporation of TOL inside the lipid matrix which led to more defects 
in the lipid crystal lattice. This decrease in the melting point may be 
due to the presence of surfactant, the nanoparticle size and the high 
surface area (Kelvin effect) [42]. Kelvin suggested that the melting 
temperature of the small particles is smaller than that of the bulk 
materials. 
 
 
Fig. 4: Differential scanning calorimetry thermograms of pure TOL, Dermarol CCT, Physical mixture and NLC formulation (NLC 45R), 
displaced for better comparison 
 
In vitro antifungal activity of tolnaftate nanostructured lipid 
carrier compared to tolnaftate solution against candida albicans 
Preparation of working solution of tolnaftate nanostructured lipid 
carriers and tolnaftate solution  
Agar cup-plate method 
Antifungal activity was conducted for the two formulas of tolnaftate 
using ten clinical C. albicans isolates. Inhibition zone diameters have 
shown the non-significant difference in antifungal activity for the 
Nano-formula compared to the generic formula. Two isolates were 
found resistant to tolnaftate; they showed some antifungal activity in 
concentrations above 3 ug/ml. 
Broth microdilution method  
The aim of this experiment was to determine the minimum 
inhibitory concentration (MIC) which defined as the lowest 
concentration of an antimicrobial that will inhibit the visible growth 
of a micro-organism after overnight incubation. MIC was found to be 
0.58 ug/ml for the two formulas. C. albicans causes a wide range of 
infections such as diaper candidiasis, oral and vaginal candidiasis, in 
addition to systemic infections [43]. The antifungal activity of the 
two formulas of tolnaftate showed no significant difference in 
antifungal activity and MIC. MIC was found to be 0.58 ug/ml for as 
shown in table 5. There were two resistant isolates (number 4 and 
7) which required more conc. Than the MIC to be killed. 
  
Table 5: The MIC of the 10 isolates of C. Albicans of tolnaftate nanostructured lipid carriers compared to the generic tolnaftate 
Strain number Nano-formula MIC Generic formula MIC 
1 0.58 ug/ml 0.58 ug/ml 
2 0.58 ug/ml 0.58 ug/ml 
3 0.58 ug/ml 0.58 ug/ml 
4 2.34 ug/ml 4.68 ug/ml 
5 0.58 ug/ml 0.58 ug/ml 
6 0.58 ug/ml 0.58 ug/ml 
7 4.68 ug/ml 4.68 ug/ml 
8 0.58 ug/ml 1.17 ug/ml 
9 1.17 ug/ml 1.17 ug/ml 
10 0.58 ug/ml 0.58 ug/ml 
MIC minimum inhibitory concentration 
 
CONCLUSION 
In this study tolnaftate loaded nanostructured lipid carriers were 
successfully prepared via high shear homogenization method using 
solid lipid (Naterol GMSP® P) and liquid lipids (Dermarol CCTP® P and 
Dermarol DCOP® P) in the presence of non-ionic surfactants (Tween 
80P®P and Span 20 P®P) and Lecithin as co-surfactant. The optimum NLCs 
particle size formulae were loaded with tolnaftate, the particle size, 
zeta potential, polydispersity, TEM, DCS and in vitro release kinetics 
were investigated. The antifungal activity of the two formulas of 
tolnaftate showed no significant difference in antifungal activity and 
MIC. In vitro release results indicated that formula (NLC 45R) was 
the best formula as it showed the most delayed release pattern of 
drug. Formula (NLC 45R) showed drug release pattern followed 
Higuchi kinetic model. The results of the master sizer, TEM and 
Zetasizer confirmed that particles are in nano-size range. 
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